Multinationals’ China Trial Strategies Shift As Industry Adapts
This article was originally published in PharmAsia News
Executive Summary
The year of 2013 marked a new low for clinical trial approvals (CTAs) in China. A compliance crackdown that has brought caution to multinational firms in particular has added to fast-paced changes evident in the industry, says a clinical research insider with years of experience at multinational drug makers in China.